Your missing links are here (15 November 2019)

Some of the best stuff we picked up around the Internet

- Nov. 15, 2019
News

By: Rasmus Kragh Jakobsen

Top picks

First step for CRISPR gene editing to fight cancer. The study involved just three patients - two with multiple myeloma and one with sarcoma - and shows only feasibility and safety. Scientists used CRISPR to knock out three genes to enable the patients own immune cells to attack cancer cells more aggressively. Results are very preliminary and data is to be presented at a conference in Florida next month. Also here and here.

Cellectis “Smart” CAR T-Cells Proof-of-Concept in Nature Communications study - shows solid tumor potential

'Shuttle' peptides may be an attractive alternative to viral and nonviral delivery of CRISPR ribonucleoproteins to the respiratory tract

NIH awards $89 mio. to genome editing somatic cells

Vision and opinion

Leading scientists and ethicists call for a global moratorium on heritable genome editing. »Certainly, the framework we are calling for will place major speed bumps in front of the most adventurous plans to re-engineer the human species. But the risks of the alternative — which include harming patients and eroding public trust — are much worse.«

STAT news has ingenious David Liu answer your questions on CRISPR, Prime Editing and more.

Industry

Gene editing pioneers 1 year-old company, Beam Therapeutics, to go public to develop new treatments based on base editing.

Rare disease. First nonprofit to spearhead the development of personalized CRISPR therapies - in about 1 years time. »This is just fast, rational drug design«

Synthego did the hard work and found insights on why CRISPR experiments are hard by surveying 400+ researchers

Pitch in! SynBioBeta's survey Your prediction for what the CRISPR genome editing field looks like in 10 years

Clinical Trials and regulations

Trial of Gene Therapy for Duchenne Muscular Dystrophy Put on Hold (again)

Challenges in Gene Therapy Production and Quality Control

Uh ah wow

Is there anything CRISPR can't do? Shape shifting hydrogels CRISPR as trigger to release drugs.

Researchers ask Twitter - we are getting more worried about CRISPR? Yes. It would seem so.

Long-read on what might have been a CRISPR genome engineered flower for the 2020 Olympics mascot.

Tags

HashtagArticleHashtagMissing links

Missing Links: Your missing links are here (15 November 2019)
Missing Links: Your missing links are here (15 November 2019)
CLINICAL TRIALS
Systemic Lupus Erythematosus, SLE, (NCT06255028)
Sponsors:
Century Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Chronic Granulomatous Disease, CGD, (NCT06325709)
Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT06287099)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine